Objective To evaluate the efficacy and safety of oral anticoagulants for older adult patients
with atrial fibrillation (AF). Design Pairwise and network meta-analyses. Setting and …

Abstract Background Two PD-1 (pembrolizumab, nivolumab) and one PD-L1 (atezolizumab)
inhibitors are approved for previously treated advanced non-small cell lung cancer but have …

Importance Non–vitamin K antagonist oral anticoagulants (NOACs) might be an attractive
choice for stroke prevention in people without atrial fibrillation who may harbor a potential …

Introduction and objective Health education improves the prognosis of many diseases. A
previous study in patients with atrial fibrillation (AF) showed that an educational intervention …

Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Background: We conducted a multicenter retrospective cohort study to elucidate the
characteristics of intracranial hemorrhage (ICH) in patients with atrial fibrillation treated with …

BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after standard
diagnostic tests. Long-term implantable cardiac monitors may be better at diagnosing atrial …

Background Trends in the use of antithrombotic drugs in elderly patients with atrial fibrillation
(AF) are largely unknown. We estimated the prevalence of AF in an older population, and …

Background Oral anticoagulants are used for stroke prevention in patients with atrial
fibrillation, the most common cardiac arrhythmia in older adults. The aim of our study was to …

Background The cause of ischemic stroke or transient ischemic attack (TIA) remains unclear
after initial cardiac monitoring in approximately one‐third of patients. Randomized controlled …